Literature DB >> 24841535

Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy.

Jungsun Park1, Haiyan Li, Mingjun Zhang, Yong Lu, Bangxing Hong, Yuhuan Zheng, Jin He, Jing Yang, Jianfei Qian, Qing Yi.   

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells to initiate immune responses, and DC survival time is important for affecting the strength of T-cell responses. Interleukin (IL)-9-producing T-helper (Th)-9 cells play an important role in anti-tumor immunity. However, it is unclear how Th9 cells communicate with DCs. In this study, we investigated whether murine Th9 cells affected the survival of myeloid DCs. DCs derived from bone marrow of C57BL/6 mice were cocultured with Th9 cells from OT-II mice using transwell, and the survival of DCs was examined. DCs cocultured with Th9 cells had longer survival and fewer apoptotic cells than DCs cultured alone in vitro. In melanoma B16-OVA tumor-bearing mice, DCs conditioned by Th9 cells lived longer and induced stronger anti-tumor response than control DCs did in vivo. Mechanistic studies revealed that IL-3 but not IL-9 secreted by Th9 cells was responsible for the prolonged survival of DCs. IL-3 upregulated the expression of anti-apoptotic protein Bcl-xL and activated p38, ERK and STAT5 signaling pathways in DCs. Taken together, our data provide the first evidence that Th9 cells can promote the survival of DCs through IL-3, and will be helpful for designing Th9 cell immunotherapy and more effective DC vaccine for human cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841535      PMCID: PMC4200484          DOI: 10.1007/s00262-014-1557-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

Review 1.  IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.

Authors:  E P Reddy; A Korapati; P Chaturvedi; S Rane
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

2.  Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions.

Authors:  A J Miga; S R Masters; B G Durell; M Gonzalez; M K Jenkins; C Maliszewski; H Kikutani; W F Wade; R J Noelle
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

3.  A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern.

Authors:  Susanne Ebner; Susanne Hofer; Van Anh Nguyen; Christina Fürhapter; Manfred Herold; Peter Fritsch; Christine Heufler; Nikolaus Romani
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

4.  Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties.

Authors:  Christel Buelens; Emmanuel J Bartholomé; Zoulikha Amraoui; Michael Boutriaux; Isabelle Salmon; Kris Thielemans; Fabienne Willems; Michel Goldman
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway.

Authors:  Yunji Park; Seung Woo Lee; Young Chul Sung
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

6.  Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells.

Authors:  Valérie Staudt; Evita Bothur; Matthias Klein; Karen Lingnau; Sebastian Reuter; Nadine Grebe; Bastian Gerlitzki; Markus Hoffmann; Alexander Ulges; Christian Taube; Nina Dehzad; Marc Becker; Michael Stassen; Andrea Steinborn; Michael Lohoff; Hansjörg Schild; Edgar Schmitt; Tobias Bopp
Journal:  Immunity       Date:  2010-07-30       Impact factor: 31.745

Review 7.  Cancer immunotherapy via dendritic cells.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

8.  The development, maturation, and turnover rate of mouse spleen dendritic cell populations.

Authors:  A T Kamath; J Pooley; M A O'Keeffe; D Vremec; Y Zhan; A M Lew; A D'Amico; L Wu; D F Tough; K Shortman
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

9.  The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation.

Authors:  Hua-Chen Chang; Sarita Sehra; Ritobrata Goswami; Weiguo Yao; Qing Yu; Gretta L Stritesky; Rukhsana Jabeen; Carl McKinley; Ayele-Nati Ahyi; Ling Han; Evelyn T Nguyen; Michael J Robertson; Narayanan B Perumal; Robert S Tepper; Stephen L Nutt; Mark H Kaplan
Journal:  Nat Immunol       Date:  2010-05-02       Impact factor: 25.606

10.  TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.

Authors:  R Josien; H L Li; E Ingulli; S Sarma; B R Wong; M Vologodskaia; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  10 in total

Review 1.  The development and in vivo function of T helper 9 cells.

Authors:  Mark H Kaplan; Matthew M Hufford; Matthew R Olson
Journal:  Nat Rev Immunol       Date:  2015-04-07       Impact factor: 53.106

Review 2.  The dichotomous function of interleukin-9 in cancer diseases.

Authors:  K Gerlach; B Weigmann
Journal:  J Mol Med (Berl)       Date:  2019-08-08       Impact factor: 4.599

Review 3.  TH9 cells in anti-tumor immunity.

Authors:  Thaiz Rivera Vargas; Etienne Humblin; Frédérique Végran; François Ghiringhelli; Lionel Apetoh
Journal:  Semin Immunopathol       Date:  2016-11-10       Impact factor: 9.623

4.  Induction of specific T helper-9 cells to inhibit glioma cell growth.

Authors:  Haiyan Zheng; Baohua Yang; Dedong Xu; Wenbo Wang; Jie Tan; Liyuan Sun; Qinghua Li; Li Sun; Xuewei Xia
Journal:  Oncotarget       Date:  2017-01-17

Review 5.  TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer.

Authors:  Yan Li; Qing Yu; Zhengguo Zhang; Jian Wang; Simin Li; Jiangyuan Zhang; Guangwei Liu
Journal:  Oncotarget       Date:  2016-10-25

Review 6.  Th9 Cell Differentiation and Its Dual Effects in Tumor Development.

Authors:  Tao Chen; Jufeng Guo; Zhenhai Cai; Binghao Li; Lingling Sun; Yingying Shen; Shengdong Wang; Zhan Wang; Zenan Wang; Yucheng Wang; Hao Zhou; Zhijian Cai; Zhaoming Ye
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

7.  IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling.

Authors:  Gang Xue; Guangxu Jin; Jing Fang; Yong Lu
Journal:  Nat Commun       Date:  2019-03-26       Impact factor: 14.919

8.  Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response.

Authors:  H Fang; R Li; Y Gu; Yuchao Fei; Kaifeng Jin; Yifan Chen; Yifan Cao; Xin Liu; Kunpeng Lv; Jieti Wang; Kuan Yu; Chao Lin; Hao Liu; He Li; Hongyong He; Weijuan Zhang; Heng Zhang; Zhenbin Shen
Journal:  Oncoimmunology       Date:  2020-12-15       Impact factor: 8.110

Review 9.  Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer.

Authors:  Jarupa Soongsathitanon; Pranisa Jamjuntra; Nuttavut Sumransub; Supaporn Yangngam; Marjorie De la Fuente; Glauben Landskron; Peti Thuwajit; Marcela A Hermoso; Chanitra Thuwajit
Journal:  J Immunol Res       Date:  2021-07-13       Impact factor: 4.818

10.  P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.

Authors:  Luiz Antonio Lupi; Flávia Karina Delella; Maira Smaniotto Cucielo; Graziela Gorete Romagnoli; Ramon Kaneno; Iseu da Silva Nunes; Raquel Fantin Domeniconi; Marcelo Martinez; Francisco Eduardo Martinez; Wagner José Fávaro; Luiz Gustavo de Almeida Chuffa
Journal:  Molecules       Date:  2019-12-18       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.